FY2028 Earnings Estimate for Kymera Therapeutics, Inc. Issued By B. Riley (NASDAQ:KYMR)

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Analysts at B. Riley upped their FY2028 EPS estimates for Kymera Therapeutics in a research note issued on Monday, July 8th. B. Riley analyst K. Patel now expects that the company will post earnings of ($4.48) per share for the year, up from their previous estimate of ($4.60). B. Riley has a “Neutral” rating and a $36.00 price target on the stock. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.86) per share.

KYMR has been the subject of a number of other research reports. HC Wainwright restated a “buy” rating and set a $46.00 target price on shares of Kymera Therapeutics in a research report on Monday, June 17th. Oppenheimer reissued an “outperform” rating and issued a $52.00 target price on shares of Kymera Therapeutics in a research note on Wednesday. Seven analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $42.09.

Kymera Therapeutics Price Performance

KYMR opened at $39.00 on Thursday. The firm has a market cap of $2.39 billion, a P/E ratio of -15.54 and a beta of 2.22. Kymera Therapeutics has a 1-year low of $9.60 and a 1-year high of $45.31. The company has a 50 day simple moving average of $33.84 and a two-hundred day simple moving average of $34.66.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, May 2nd. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.04. The company had revenue of $10.30 million during the quarter, compared to analyst estimates of $14.24 million. Kymera Therapeutics had a negative net margin of 194.67% and a negative return on equity of 31.92%. The firm’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.70) earnings per share.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bruce Booth sold 16,740 shares of the firm’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $35.45, for a total transaction of $593,433.00. Following the completion of the transaction, the director now directly owns 803,792 shares of the company’s stock, valued at approximately $28,494,426.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Kymera Therapeutics news, Director Bruce Booth sold 16,740 shares of the firm’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $35.45, for a total transaction of $593,433.00. Following the completion of the transaction, the director now directly owns 803,792 shares of the company’s stock, valued at approximately $28,494,426.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Joanna Horobin sold 8,500 shares of the firm’s stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $32.99, for a total transaction of $280,415.00. The disclosure for this sale can be found here. Insiders sold 479,200 shares of company stock valued at $18,219,660 in the last three months. 15.82% of the stock is owned by insiders.

Hedge Funds Weigh In On Kymera Therapeutics

Institutional investors have recently bought and sold shares of the business. DekaBank Deutsche Girozentrale increased its holdings in shares of Kymera Therapeutics by 7.1% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 23,562 shares of the company’s stock valued at $950,000 after purchasing an additional 1,562 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Kymera Therapeutics during the 1st quarter valued at approximately $207,000. Artal Group S.A. increased its holdings in shares of Kymera Therapeutics by 19.6% during the 1st quarter. Artal Group S.A. now owns 3,027,135 shares of the company’s stock valued at $121,691,000 after purchasing an additional 496,400 shares in the last quarter. Comerica Bank increased its holdings in shares of Kymera Therapeutics by 13.7% during the 1st quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after purchasing an additional 400 shares in the last quarter. Finally, California State Teachers Retirement System increased its holdings in shares of Kymera Therapeutics by 5.5% during the 1st quarter. California State Teachers Retirement System now owns 40,423 shares of the company’s stock valued at $1,625,000 after purchasing an additional 2,102 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.